We and others have previously performed large-scale genome sequencing to comprehensively characterize cancer genome alterations in SCLC, which showed universal biallelic losses of the tumour suppressors TP53 and RB1, additional alterations to histone-modifying enzymes and cell cycle regulators, and MYC transcription factor amplifications5–7. The gene discussed is TP53; the disease is neoplasm.